Cetera Investment Advisers
ADMA icon

Cetera Investment Advisers’s ADMA Biologics ADMA Stock Holding History

Cetera Investment Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Sell
128,233
-48,098
-27% -$438K ﹤0.01% 2997
2026
Q1 		$1.59M Sell
176,331
-7,100
-4% -$112K ﹤0.01% 2490
2025
Q4 		$3.35M Buy
183,431
+7,840
+4% +$132K ﹤0.01% 1763
2025
Q3 		$2.57M Buy
175,591
+109,096
+164% +$1.87M ﹤0.01% 1957
2025
Q2 		$1.21M Buy
66,495
+15,984
+32% +$326K ﹤0.01% 2212
2025
Q1 		$1M Buy
50,511
+670
+1% +$11.6K ﹤0.01% 2259
2024
Q4 		$855K Sell
49,841
-6,086
-11% -$114K ﹤0.01% 2275
2024
Q3 		$1.12M Buy
55,927
+13,774
+33% +$214K ﹤0.01% 2045
2024
Q2 		$471K Buy
+42,153
New +$354K ﹤0.01% 2636

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Cetera Investment Advisers's ADMA Position: Q2 2026 in Review

Cetera Investment Advisers reduced its ADMA Biologics (ADMA) stake by 27% in Q2 2026, selling an estimated $438K and leaving 128,233 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2997.

Cetera Investment Advisers first reported a position in ADMA in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.35M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Cetera Investment Advisers held 128,233 shares of ADMA Biologics worth $1.07M as of Q2 2026.
  • Cetera Investment Advisers sold 48,098 ADMA Biologics shares in Q2 2026, an estimated $438K.
  • ADMA Biologics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #2997 holding.
  • Cetera Investment Advisers first reported a position in ADMA Biologics in Q2 2024 and has held it in 9 quarters since.
  • Cetera Investment Advisers's ADMA Biologics position peaked at $3.35M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.